Impact of frailty and mobility on mortality and symptomatic improvement in TAVR

Samer Fawaz; Christopher Cook; Ashni Chani; Sarosh Khan; Sanjay Rajput; John Davies; Thomas R Keeble; Rajesh Aggarwal; Rohan Jagathesan; Ozan M Demir

doi:10.1016/j.ijcha.2025.101725

Impact of frailty and mobility on mortality and symptomatic improvement in TAVR

Int J Cardiol Heart Vasc. 2025 Jun 19:59:101725. doi: 10.1016/j.ijcha.2025.101725. eCollection 2025 Aug.

Authors

Samer Fawaz^{1

2}, Christopher Cook^{1

2}, Ashni Chani¹, Sarosh Khan^{1

2}, Sanjay Rajput³, John Davies^{1

2}, Thomas R Keeble^{1

2}, Rajesh Aggarwal¹, Rohan Jagathesan¹, Ozan M Demir^{1

2}

Affiliations

¹ Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon, UK.
² Anglia Ruskin School of Medicine & MTRC, Anglia Ruskin University, Chelmsford, UK.
³ University College London, London, UK.

Abstract

•Frailty and poor mobility predict higher 1-year mortality and reduced symptomatic improvement after TAVI.•Diabetes, chronic kidney disease, and male sex are linked to increased 1-year mortality.•Respiratory disease and female sex are associated with less symptomatic benefit post-TAVI.

Keywords: Aortic stenosis; Frailty; Mobility; Prognosis; TAVI; TAVR.

Publication types

Letter